Naturally occurring
neurotoxins, 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines (DHTIQs), thought to be the causative agents of
Parkinsonism. DHTIQs including
norsalsolinol have been found in the mammalian central nervous system.
Norsalsolinol can be formed by a non-enzymatic Pictet-Spengler condensation reaction between
dopamine and
formaldehyde, and has been detected in the urine of Parkinsonian patients. However, the effects of DHTIQs on the secretion of
dopamine, as well as other
neurotransmitters, are not well understood. This study investigated the effects of
norsalsolinol on
dopamine secretion from
nerve growth factor-differentiated PC12 cells.
Norsalsolinol (1-100 microM) pretreatment suppressed both
ATP (100 microM)- and K(+) (50 mM)-induced
dopamine secretion from PC12 cells in a concentration-dependent fashion, but did not affect basal
dopamine secretion. In
beta-escin-permeabilized PC12 cells,
norsalsolinol pretreatment suppressed Ca(2+) (pCa=4-8)-induced
dopamine secretion, but did not inhibit the
secretagogue-induced change in intracellular Ca(2+) concentration. These results suggest that
norsalsolinol causes the inhibition of
secretagogue-induced
dopamine secretion from PC12 cells without altering intracellular Ca(2+) concentration. Inhibition of
dopamine secretion by
norsalsolinol may also be involved in postural abnormality in
Parkinson's disease.